7 results on '"Pranjic B"'
Search Results
2. TSPAN6 is a suppressor of Ras-driven cancer
- Author
-
Humbert, PO, Pryjda, TZ, Pranjic, B, Farrell, A, Fujikura, K, de Matos Simoes, R, Karim, R, Kozieradzki, I, Cronin, SJF, Neely, GG, Meyer, TF, Hagelkruys, A, Richardson, HE, Penninger, JM, Humbert, PO, Pryjda, TZ, Pranjic, B, Farrell, A, Fujikura, K, de Matos Simoes, R, Karim, R, Kozieradzki, I, Cronin, SJF, Neely, GG, Meyer, TF, Hagelkruys, A, Richardson, HE, and Penninger, JM
- Abstract
Oncogenic mutations in the small GTPase RAS contribute to ~30% of human cancers. In a Drosophila genetic screen, we identified novel and evolutionary conserved cancer genes that affect Ras-driven tumorigenesis and metastasis in Drosophila including confirmation of the tetraspanin Tsp29Fb. However, it was not known whether the mammalian Tsp29Fb orthologue, TSPAN6, has any role in RAS-driven human epithelial tumors. Here we show that TSPAN6 suppressed tumor growth and metastatic dissemination of human RAS activating mutant pancreatic cancer xenografts. Whole-body knockout as well as tumor cell autonomous inactivation using floxed alleles of Tspan6 in mice enhanced KrasG12D-driven lung tumor initiation and malignant progression. Mechanistically, TSPAN6 binds to the EGFR and blocks EGFR-induced RAS activation. Moreover, we show that inactivation of TSPAN6 induces an epithelial-to-mesenchymal transition and inhibits cell migration in vitro and in vivo. Finally, low TSPAN6 expression correlates with poor prognosis of patients with lung and pancreatic cancers with mesenchymal morphology. Our results uncover TSPAN6 as a novel tumor suppressor receptor that controls epithelial cell identify and restrains RAS-driven epithelial cancer.
- Published
- 2022
3. TSPAN6 is a suppressor of Ras-driven cancer.
- Author
-
Humbert PO, Pryjda TZ, Pranjic B, Farrell A, Fujikura K, de Matos Simoes R, Karim R, Kozieradzki I, Cronin SJF, Neely GG, Meyer TF, Hagelkruys A, Richardson HE, and Penninger JM
- Subjects
- Animals, Carcinogenesis genetics, Cell Line, Tumor, Cell Transformation, Neoplastic genetics, Genes, ras, Humans, Mammals genetics, Mammals metabolism, Mice, Mutation, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Oncogenes, Pancreatic Neoplasms pathology, Tetraspanins genetics, Tetraspanins metabolism
- Abstract
Oncogenic mutations in the small GTPase RAS contribute to ~30% of human cancers. In a Drosophila genetic screen, we identified novel and evolutionary conserved cancer genes that affect Ras-driven tumorigenesis and metastasis in Drosophila including confirmation of the tetraspanin Tsp29Fb. However, it was not known whether the mammalian Tsp29Fb orthologue, TSPAN6, has any role in RAS-driven human epithelial tumors. Here we show that TSPAN6 suppressed tumor growth and metastatic dissemination of human RAS activating mutant pancreatic cancer xenografts. Whole-body knockout as well as tumor cell autonomous inactivation using floxed alleles of Tspan6 in mice enhanced Kras
G12D -driven lung tumor initiation and malignant progression. Mechanistically, TSPAN6 binds to the EGFR and blocks EGFR-induced RAS activation. Moreover, we show that inactivation of TSPAN6 induces an epithelial-to-mesenchymal transition and inhibits cell migration in vitro and in vivo. Finally, low TSPAN6 expression correlates with poor prognosis of patients with lung and pancreatic cancers with mesenchymal morphology. Our results uncover TSPAN6 as a novel tumor suppressor receptor that controls epithelial cell identify and restrains RAS-driven epithelial cancer., (© 2022. Crown.)- Published
- 2022
- Full Text
- View/download PDF
4. Correction: TSPAN6 is a suppressor of Ras-driven cancer.
- Author
-
Humbert PO, Pryjda TZ, Pranjic B, Farrell A, Fujikura K, de Matos Simoes R, Karim R, Kozieradzki I, Cronin SJF, Neely GG, Meyer TF, Hagelkruys A, Richardson HE, and Penninger JM
- Published
- 2022
- Full Text
- View/download PDF
5. RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy.
- Author
-
Paolino M, Koglgruber R, Cronin SJF, Uribesalgo I, Rauscher E, Harreiter J, Schuster M, Bancher-Todesca D, Pranjic B, Novatchkova M, Fededa JP, White AJ, Sigl V, Dekan S, Penz T, Bock C, Kenner L, Holländer GA, Anderson G, Kautzky-Willer A, and Penninger JM
- Subjects
- Adipocytes pathology, Animals, Cell Proliferation, Diabetes, Gestational etiology, Diabetes, Gestational metabolism, Diabetes, Gestational pathology, Epithelial Cells immunology, Female, Fetus immunology, Fetus metabolism, Fetus pathology, Glucose metabolism, Glucose Intolerance genetics, Humans, Intra-Abdominal Fat pathology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Placenta immunology, Placenta pathology, Pregnancy, Receptor Activator of Nuclear Factor-kappa B deficiency, Receptor Activator of Nuclear Factor-kappa B genetics, T-Lymphocytes, Regulatory cytology, Thymus Gland cytology, Transcription Factors metabolism, AIRE Protein, Diabetes, Gestational immunology, Fetal Death etiology, Receptor Activator of Nuclear Factor-kappa B metabolism, T-Lymphocytes, Regulatory immunology, Thymus Gland immunology
- Abstract
Successful pregnancies rely on adaptations within the mother
1 , including marked changes within the immune system2 . It has long been known that the thymus, the central lymphoid organ, changes markedly during pregnancy3 . However, the molecular basis and importance of this process remain largely obscure. Here we show that the osteoclast differentiation receptor RANK4,5 couples female sex hormones to the rewiring of the thymus during pregnancy. Genetic deletion of Rank (also known as Tnfrsf11a) in thymic epithelial cells results in impaired thymic involution and blunted expansion of natural regulatory T (Treg ) cells in pregnant female mice. Sex hormones, in particular progesterone, drive the development of thymic Treg cells through RANK in a manner that depends on AIRE+ medullary thymic epithelial cells. The depletion of Rank in the mouse thymic epithelium results in reduced accumulation of natural Treg cells in the placenta, and an increase in the number of miscarriages. Thymic deletion of Rank also results in impaired accumulation of Treg cells in visceral adipose tissue, and is associated with enlarged adipocyte size, tissue inflammation, enhanced maternal glucose intolerance, fetal macrosomia, and a long-lasting transgenerational alteration in glucose homeostasis, which are all key hallmarks of gestational diabetes. Transplantation of Treg cells rescued fetal loss, maternal glucose intolerance and fetal macrosomia. In human pregnancies, we found that gestational diabetes also correlates with a reduced number of Treg cells in the placenta. Our findings show that RANK promotes the hormone-mediated development of thymic Treg cells during pregnancy, and expand the functional role of maternal Treg cells to the development of gestational diabetes and the transgenerational metabolic rewiring of glucose homeostasis.- Published
- 2021
- Full Text
- View/download PDF
6. AIF-regulated oxidative phosphorylation supports lung cancer development.
- Author
-
Rao S, Mondragón L, Pranjic B, Hanada T, Stoll G, Köcher T, Zhang P, Jais A, Lercher A, Bergthaler A, Schramek D, Haigh K, Sica V, Leduc M, Modjtahedi N, Pai TP, Onji M, Uribesalgo I, Hanada R, Kozieradzki I, Koglgruber R, Cronin SJ, She Z, Quehenberger F, Popper H, Kenner L, Haigh JJ, Kepp O, Rak M, Cai K, Kroemer G, and Penninger JM
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Datasets as Topic, Disease Progression, Glycolysis, Humans, Lung Neoplasms pathology, Mice, Mice, Inbred C57BL, Oxidative Phosphorylation, Apoptosis Inducing Factor physiology, Carcinogenesis metabolism, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms metabolism
- Abstract
Cancer is a major and still increasing cause of death in humans. Most cancer cells have a fundamentally different metabolic profile from that of normal tissue. This shift away from mitochondrial ATP synthesis via oxidative phosphorylation towards a high rate of glycolysis, termed Warburg effect, has long been recognized as a paradigmatic hallmark of cancer, supporting the increased biosynthetic demands of tumor cells. Here we show that deletion of apoptosis-inducing factor (AIF) in a Kras
G12D -driven mouse lung cancer model resulted in a marked survival advantage, with delayed tumor onset and decreased malignant progression. Mechanistically, Aif deletion leads to oxidative phosphorylation (OXPHOS) deficiency and a switch in cellular metabolism towards glycolysis in non-transformed pneumocytes and at early stages of tumor development. Paradoxically, although Aif-deficient cells exhibited a metabolic Warburg profile, this bioenergetic change resulted in a growth disadvantage of KrasG12D -driven as well as Kras wild-type lung cancer cells. Cell-autonomous re-expression of both wild-type and mutant AIF (displaying an intact mitochondrial, but abrogated apoptotic function) in Aif-knockout KrasG12D mice restored OXPHOS and reduced animal survival to the same level as AIF wild-type mice. In patients with non-small cell lung cancer, high AIF expression was associated with poor prognosis. These data show that AIF-regulated mitochondrial respiration and OXPHOS drive the progression of lung cancer.- Published
- 2019
- Full Text
- View/download PDF
7. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
- Author
-
Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, and Penninger JM
- Subjects
- Adaptor Proteins, Signal Transducing deficiency, Adaptor Proteins, Signal Transducing genetics, Animals, Anticoagulants pharmacology, Anticoagulants therapeutic use, Female, Killer Cells, Natural drug effects, Killer Cells, Natural metabolism, Male, Mammary Neoplasms, Experimental drug therapy, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental immunology, Melanoma, Experimental drug therapy, Melanoma, Experimental genetics, Melanoma, Experimental immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Metastasis drug therapy, Neoplasm Metastasis prevention & control, Proto-Oncogene Proteins antagonists & inhibitors, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-cbl deficiency, Proto-Oncogene Proteins c-cbl genetics, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Ubiquitin-Protein Ligases deficiency, Ubiquitin-Protein Ligases genetics, Ubiquitination, Warfarin pharmacology, Warfarin therapeutic use, c-Mer Tyrosine Kinase, Axl Receptor Tyrosine Kinase, Adaptor Proteins, Signal Transducing metabolism, Killer Cells, Natural immunology, Mammary Neoplasms, Experimental pathology, Melanoma, Experimental pathology, Neoplasm Metastasis immunology, Proto-Oncogene Proteins c-cbl metabolism, Receptor Protein-Tyrosine Kinases metabolism, Ubiquitin-Protein Ligases metabolism
- Abstract
Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a 'pill' that awakens the innate immune system to kill cancer metastases.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.